Carl Zeiss Meditec achieves revenue growth and stable operating profit
Further recovery in order entry compared to prior year.
Carl Zeiss Meditec generated revenue of €1,050.5m in the first half of fiscal year 2024/25 (prior year: €947.2m), including the DORC consolidation, corresponding to growth of +10.9% (adjusted for currency effects: +10.6%). Adjusted for currency and acquisition effects, revenue was slightly below the prior year figure at -0.5%. Order entry rose significantly by +33.4%. EBITA increased to around €113.6m (prior year: €113.2m). The EBITA1 margin was 10.8% (prior year: 12.0%).
Dr. Markus Weber, CEO of Carl Zeiss Meditec AG, comments on the first six months of the year: “Over the course of the second quarter in particular, we saw a clear upturn in demand for refractive surgery consumables in China, as we already reported in our ad hoc announcement on April 15, 2025. Unfortunately, uncertainties surrounding US trade tariffs and currency risks are currently weighing on the outlook. We are therefore maintaining our previous guidance of stable to slightly increasing EBITA for the remainder of the fiscal year until further notice.”
You can find further information here.
BREAKING